Bactimicina for Sore Throat

Description

Bactimicina® is a benzocaine oral anesthetic formulated in the form of lozenges. Each package contains 18 lozenges, which are designed to provide localized relief. The product is characterized by its orange flavor, enhancing palatability for users.

Uses and Indications

This drug is indicated for the temporary relief of occasional minor irritation, pain, sore mouth, and sore throat.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 5 years and older, the recommended dosage is to dissolve 1 lozenge slowly in the mouth. This may be repeated every 2 hours as needed or as directed by a healthcare professional.

The use of this medication is not recommended for children under 5 years of age.

Contraindications

Use is contraindicated in the following situations:

• The product should not be used for teething due to the potential for adverse effects in this context.

• It is contraindicated in children under 5 years of age, as safety and efficacy have not been established in this population.

• Exceeding the recommended dosage is also contraindicated, as it may lead to increased risk of adverse reactions.

Warnings and Precautions

Use of this product may lead to methemoglobinemia, a serious condition characterized by reduced oxygen transport in the blood. This risk exists even in individuals who have previously used the product without issue. Healthcare professionals should advise patients to discontinue use and seek immediate medical attention if they or a child exhibit any of the following symptoms: pale, gray, or blue-colored skin (cyanosis), shortness of breath, headache, dizziness or lightheadedness, rapid heart rate, or fatigue.

Patients with a known allergy to local anesthetics, including procaine, butacaine, benzocaine, or any other "caine" anesthetics, should not use this product. In the event of a skin reaction, it is imperative to stop use and seek medical assistance without delay.

In cases of severe sore throat that persists for more than two days, or if it is accompanied by fever, headache, rash, swelling, nausea, or vomiting, patients should be advised to consult a physician promptly.

Healthcare professionals should instruct patients to discontinue use and seek medical advice if any of the following occur: sore mouth symptoms do not improve within seven days, irritation, pain, or redness persists or worsens, or if swelling, rash, or fever develops.

In the event of an overdose or if more than the recommended amount for pain relief is accidentally ingested, immediate medical assistance should be sought, or the local Poison Control Center should be contacted.

Side Effects

The use of this product may lead to serious adverse reactions, including methemoglobinemia, a condition that significantly reduces the oxygen-carrying capacity of the blood. This serious condition requires prompt treatment and can occur even in patients who have previously used the product without issue. Patients should discontinue use and seek immediate medical attention if they or a child in their care experience symptoms such as pale, gray, or blue-colored skin (cyanosis), shortness of breath, headache, dizziness or lightheadedness, rapid heart rate, or fatigue.

Patients with a known history of allergy to local anesthetics, including procaine, butacaine, benzocaine, or any other "caine" anesthetics, should avoid using this product. In the event of a skin reaction, it is imperative to stop use and seek medical assistance immediately.

Common adverse reactions may include sore throat. If a sore throat is severe, persists for more than two days, or is accompanied by fever, headache, rash, swelling, nausea, or vomiting, patients are advised to consult a healthcare professional promptly.

Patients should also discontinue use and consult a doctor if sore mouth symptoms do not improve within seven days, or if irritation, pain, or redness persists or worsens. Additionally, any development of swelling, rash, or fever warrants immediate medical consultation.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions between the drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Bactimicina for Sore Throat (benzocaine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 5 years of age should not use this medication. For children aged 5 years and older, the recommended dosage is to dissolve 1 lozenge slowly in the mouth, which may be repeated every 2 hours as needed or as directed by a healthcare professional. Caution is advised in the administration of this product to ensure safety and efficacy in the pediatric population.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments, special monitoring, or safety considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdose, or if an individual accidentally ingests more than the recommended dosage for pain relief, it is imperative to seek medical assistance promptly. Healthcare professionals should advise patients or caregivers to contact a Poison Control Center immediately for guidance.

Symptoms of overdose may vary depending on the specific substance involved; therefore, a thorough assessment and monitoring of the patient are essential. It is crucial to provide supportive care and symptomatic treatment as necessary.

Management of an overdose should be conducted in a medical facility where appropriate interventions can be implemented. This may include monitoring vital signs, administering activated charcoal if indicated, and providing any specific antidotes or treatments as required based on the clinical scenario.

Healthcare providers are encouraged to remain vigilant and proactive in managing potential overdose situations to ensure patient safety and optimal outcomes.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

The use of this product has been associated with reports of methemoglobinemia, a serious condition characterized by reduced oxygen transport in the blood, which requires prompt medical intervention. Cases of methemoglobinemia have been documented even in individuals who have previously used the product without incident.

In instances where symptoms such as pale, gray, or blue-colored skin (cyanosis), shortness of breath, headache, dizziness or lightheadedness, rapid heart rate, or fatigue or lack of energy develop, it is advised to discontinue use immediately and seek medical attention. Additionally, any occurrence of skin reactions warrants the cessation of use and prompt medical evaluation.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose or if more than the recommended amount for pain relief is accidentally ingested.

It is important to inform patients that this product is not intended for use in teething and should not be administered to children under 5 years of age.

Patients should be instructed to discontinue use and consult a doctor if symptoms of a sore mouth do not improve within 7 days. Additionally, they should be made aware that they need to stop using the product and seek medical advice if they experience persistent or worsening irritation, pain, or redness.

Patients should also be cautioned to stop use and contact a healthcare professional if they notice any swelling, rash, or fever developing. Furthermore, healthcare providers should emphasize the importance of adhering to the recommended dosage and not exceeding it while using this product.

Storage and Handling

The product is supplied in a configuration that ensures optimal integrity and efficacy. It is essential to protect the product from moisture to maintain its quality. The recommended storage condition is at room temperature, ensuring that the product remains stable and effective. Healthcare professionals are advised to check the expiration date before use to ensure the product's safety and effectiveness.

Additional Clinical Information

The medication is administered orally, with specific instructions for different age groups. Adults and children aged 5 years and older should dissolve one lozenge slowly in the mouth, with the option to repeat every two hours as needed or as directed by a healthcare professional. Use is not recommended for children under 5 years of age.

Clinicians should counsel patients to consult a health professional if they are pregnant or breastfeeding. It is important to keep the medication out of reach of children. In the event of an overdose or if more than the recommended amount is swallowed, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Information (PDF)

This file contains official product information for Bactimicina for Sore Throat, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)